Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, Neal K Lakdawala, Matthew T Wheeler, Anjali Owens, Milos Kubanek, Wojciech Wojakowski, Morten K Jensen, Juan Gimeno-Blanes, Kia Afshar, Jonathan Myers, Sheila M Hegde, Scott D Solomon, Amy J Sehnert, David Zhang, Wanying Li, Mondira Bhattacharya, Jay M Edelberg, Cynthia Burstein Waldman, Steven J Lester, Andrew Wang, Carolyn Y Ho, Daniel Jacoby
BACKGROUND: Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy...
September 12, 2020: Lancet
Carolyn Y Ho, Matthew E Mealiffe, Richard G Bach, Mondira Bhattacharya, Lubna Choudhury, Jay M Edelberg, Sheila M Hegde, Daniel Jacoby, Neal K Lakdawala, Steven J Lester, Yanfei Ma, Ali J Marian, Sherif F Nagueh, Anjali Owens, Florian Rader, Sara Saberi, Amy J Sehnert, Mark V Sherrid, Scott D Solomon, Andrew Wang, Omar Wever-Pinzon, Timothy C Wong, Stephen B Heitner
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. By altering the contractile mechanics of the cardiomyocyte, myosin inhibitors have the potential to modify pathophysiology and improve symptoms associated with HCM. OBJECTIVES: MAVERICK-HCM (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored the safety and efficacy of mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, in nHCM...
June 2, 2020: Journal of the American College of Cardiology
Derek Crinion, Hoshiar Abdollah, Adrian Baranchuk
No abstract text is available yet for this article.
June 23, 2020: Circulation
Son V Pham, Robert J Chilton
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling...
July 1, 2017: American Journal of Cardiology
Tao You, Xing-Guang Liu, Xiao-Dong Hou, Xin-Kuan Wang, Han-Hui Xie, Fan Ding, Kang Yi, Peng Zhang, Xiao-Dong Xie
OBJECTIVE: As a class of cholesterol-lowering drugs, statins have been reported to cause unexpected decrease in blood pressure (BP). However, most studies in this issue were subject to inadequate study design or very small sample size. The present study was designed to examine the BP-lowering effect of various statins. METHODS: Here we retrieved 5.9 million clinical reports submitted to FDA Adverse Event Reporting System (FAERS) from 2004 to 2015. Meta-analysis was performed to estimate the overall reporting odds ratio (ROR) of hypotension adverse events concurrent with various statins (i...
2017: Clinical and Experimental Hypertension: CHE
Jorge Aceituno, Pamela Ramírez
New England Journal of Medicine, Volume 381, Issue 14, October 2019.
October 3, 2019: New England Journal of Medicine
Estelle Gandjbakhch, Alban Redheuil, Françoise Pousset, Philippe Charron, Robert Frank
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inherited cardiomyopathy that can lead to sudden cardiac death and heart failure. Our understanding of its pathophysiology and clinical expressivity is continuously evolving. The diagnosis of ARVC/D remains particularly challenging due to the absence of specific unique diagnostic criteria, its variable expressivity, and incomplete penetrance. Advances in genetics have enlarged the clinical spectrum of the disease, highlighting possible phenotypes that overlap with arrhythmogenic dilated cardiomyopathy and channelopathies...
August 14, 2018: Journal of the American College of Cardiology
Zakaria Jalal, Sebastien Hascoet, Alban-Elouen Baruteau, Xavier Iriart, Bernard Kreitmann, Younes Boudjemline, Jean-Benoit Thambo
Percutaneous closure has evolved to become the first-line treatment strategy for most cases of secundum atrial septal defect (ASD) in both adults and children. Its safety and efficacy have been proved; percutaneous ASD occlusion offers many advantages over surgical closure, including avoidance of cardiopulmonary bypass, avoidance of sternotomy scar, shorter hospitalization, and a potentially lower incidence of postprocedural complications. Periprocedural course and short-term outcome have been widely described, with low mortality and morbidity rates...
November 2016: Canadian Journal of Cardiology
Loren F Hiratzka, Mark A Creager, Eric M Isselbacher, Lars G Svensson, Rick A Nishimura, Robert O Bonow, Robert A Guyton, Thoralf M Sundt
Two guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA), and collaborating societies address the risk of aortic dissection in patients with bicuspid aortic valves and severe aortic enlargement: The "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease" (J Am Coll Cardiol. 2010;55:e27-130) and the "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease" (J Am Coll Cardiol...
April 2016: Journal of Thoracic and Cardiovascular Surgery
S Pasta, G Gentile, G M Raffa, D Bellavia, G Chiarello, R Liotta, A Luca, C Scardulla, M Pilato
OBJECTIVE/BACKGROUND: The development of ascending aortic dilatation in patients with bicuspid aortic valve (BAV) is highly variable, and this makes surgical decision strategies particularly challenging. The purpose of this study was to identify new predictors, other than the well established aortic size, that may help to stratify the risk of aortic dilatation in BAV patients. METHODS: Using fluid-structure interaction analysis, both haemodynamic and structural parameters exerted on the ascending aortic wall of patients with either BAV (n = 21) or tricuspid aortic valve (TAV; n = 13) with comparable age and aortic diameter (42...
August 2017: European Journal of Vascular and Endovascular Surgery
Tomasz Imiela, Andrzej Budaj
BACKGROUND: Congestion is the main cause of morbidity in patients with heart failure. Treatment of fluid overload is often challenging in everyday clinical practice. OBJECTIVE: The aim of this study was to determine the diuretic effect of acetazolamide in patients with exacerbations of chronic heart failure, in addition to their stable diuretic therapy. METHODS: This was a single-center, unblinded study. Patients hospitalized with chronic heart failure exacerbations, with left ventricular ejection fraction (EF) < 50% and signs of volume overload, with a stable dose of diuretics anticipated by the attending physician over the next 4 days, were considered eligible for the study...
December 2017: Clinical Drug Investigation
Chouchou Tang, Yizhong Zhu, Jing Zhang, Chengcheng Niu, Dan Liu, Yacong Liao, Lijun Zhu, Qinghai Peng
OBJECTIVE: The aim was to analyze left ventricular (LV) fluid dynamics in dilated cardiomyopathy (DCM) by using echocardiographic particle image velocimetry (E-PIV). METHODS: Twenty patients with DCM and twenty healthy volunteers were examined. LV ultrasound contrast was administered by intravenous bolus injection. At least three dynamic contrast-enhanced echocardiographic images of cardiac cycles from apical three-chamber view and four-chamber view were obtained...
January 2018: Echocardiography
Thomas M Ormiston, Shelley R Salpeter
Beta-adrenergic blocking agents, or beta-blockers, are indicated in the management of angina pectoris, myocardial infarction, hypertension, congestive heart failure (CHF), cardiac arrhythmias, and thyrotoxicosis, and are given to reduce perioperative complications. Despite clear evidence that they reduce morbidity and mortality, clinicians are often hesitant to administer them for fear of adverse reactions. Over the past several years, many of the contraindications traditionally listed for betablockers have been questioned and disproved...
2003: Heart Failure Monitor
S Novo, A Pinto, D Galati, A Giannola, G Forte, A Strano
This paper summarizes the results of two studies carried out to evaluate the effects of the cardioselective betablockers atenolol, acebutolol and metoprolol on peripheral circulation of the lower limbs. The 1st study was a double dummy double blind cross over placebo controlled trial carried out for 13 weeks to evaluate the effects of acebutolol (600 mg/die) and metoprolol (300 mg/die), two cardioselective betablockers, on peripheral haemodynamics in patients suffering from mild to moderate hypertension. The 2nd study was a placebo controlled trial on the effects of atenolol (100 mg/day) on haemodynamics at the calf carried out for 8 weeks in patients suffering from essential to severe moderate hypertension, part of which aged over 65 years and affected by arteriosclerosis obliterans of the lower limbs, stage I and II according to Fontaine's classification...
1985: International Angiology: a Journal of the International Union of Angiology
Rick A Nishimura, Catherine M Otto, Robert O Bonow, Blase A Carabello, John P Erwin, Lee A Fleisher, Hani Jneid, Michael J Mack, Christopher J McLeod, Patrick T O'Gara, Vera H Rigolin, Thoralf M Sundt, Annemarie Thompson
No abstract text is available yet for this article.
July 11, 2017: Journal of the American College of Cardiology
Win-Kuang Shen, Robert S Sheldon, David G Benditt, Mitchell I Cohen, Daniel E Forman, Zachary D Goldberger, Blair P Grubb, Mohamed H Hamdan, Andrew D Krahn, Mark S Link, Brian Olshansky, Satish R Raj, Roopinder Kaur Sandhu, Dan Sorajja, Benjamin C Sun, Clyde W Yancy
No abstract text is available yet for this article.
August 1, 2017: Journal of the American College of Cardiology
Anna Gomes, Andor W J M Glaudemans, Daan J Touw, Joost P van Melle, Tineke P Willems, Alexander H Maass, Ehsan Natour, Niek H J Prakken, Ronald J H Borra, Peter Paul van Geel, Riemer H J A Slart, Sander van Assen, Bhanu Sinha
Sensitivity and specificity of the modified Duke criteria for native valve endocarditis are both suboptimal, at approximately 80%. Diagnostic accuracy for intracardiac prosthetic material-related infection is even lower. Non-invasive imaging modalities could potentially improve diagnosis of infective endocarditis; however, their diagnostic value is unclear. We did a systematic literature review to critically appraise the evidence for the diagnostic performance of these imaging modalities, according to PRISMA and GRADE criteria...
January 2017: Lancet Infectious Diseases
Marie Lund, Lars Jorge Diaz, Mattis Flyvholm Ranthe, Helle Petri, Morten Duno, Inger Juncker, Hans Eiberg, John Vissing, Henning Bundgaard, Jan Wohlfahrt, Mads Melbye
AIMS: To quantify the association between myotonic dystrophy (DM) and cardiac disease in a nationwide cohort. METHODS AND RESULTS: We identified a nationwide cohort of 1146 DM patients (period 1977-2011) using the National Patient Registry (NPR) and a subcohort of 485 patients who had undergone genetic testing for DM1. Information on incident cardiac diseases was obtained from the NPR. We estimated standardized incidence ratios (SIRs) of cardiac disease compared with the background population, overall and according to selected diagnostic subgroups (cardiomyopathy, heart failure, conduction disorders, arrhythmias, and device implantation)...
August 21, 2014: European Heart Journal
Grant W Reed, Jeffrey E Rossi, Christopher P Cannon
Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins...
January 14, 2017: Lancet
2016-08-19 17:56:52
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.